Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Valuation Madness

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 03, 2021 8:13pm

235 Views

Post# 32711592

RE:RE:RE:RE:RE:RE:RE:Valuation Madness

When both programs turn into huge wins, we need to have a long term shareholders celebratory golf outing which we will name the Tanguay Invitational - Luc can choose who gets to come. Maybe he will invite Palinc2000 just to see if they can work it out. Luc deserves a lot of credit but he would also likely be the first to share that credit with the whole team, including Paul, who has done well with the good situation Luc left him, other than the share offering and the inability to get the share price valued more equitably versus other stocks.

jfm1330 wrote: Both programs are the results of the previous CEO. You know, this Tanguay guy that some here despised so much.

SPCEO1 wrote: Turning an investigator led study of HIV NASH into a full fledged general NASH phase III program is a huge success. Shareholders got a late stage program for next to nothing. Buying a cancer drug for a song and then seeing it get fast tracked by t he FDA in the pre-clincial stage is another hue success. Its not like the company has not already turned a corner with a new CEO.